Purpose: Cavotricuspid isthmus (CTI) ablation is an effective procedure for typical atrial flutter (AFL), but patients remain at an elevated risk for developing new atrial fibrillation (AF). Currently, there are limited data on the utility of CHADS-VASc score to predict new-onset AF after typical AFL ablation. In this study, we assessed whether the CHADS-VASc score is a useful predictor of new-onset AF after CTI ablation in typical AFL patients without a prior history of AF.
Methods: This was a retrospective study of 103 typical AFL patients with no prior history of AF, who underwent successful CTI ablation. The endpoint was occurrence of new-onset AF during follow-up.
Results: During a mean follow-up period of 24.6 ± 16.9 months, at least one episode of AF occurred in 33 (32%) patients. Multivariate Cox regression analysis revealed that CHADS-VASc score (hazard ratio = 1.736; 95% confidence interval = 1.370-2.201; < 0.001) was significantly associated with postablation new-onset AF (area under the curve = 0.797). A cutoff value of three stratified these patients into two groups with different incidences of postablation new-onset AF (67.9 vs. 18.7%, < 0.001).
Conclusion: The CHADS-VASc score is a useful tool for the prediction of new-onset AF after ablation of typical AFL. Patients with CHADS-VASc score ≥3 are more likely to develop new-onset AF and should be monitored more closely.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298125 | PMC |
http://dx.doi.org/10.3389/fphys.2020.00558 | DOI Listing |
Hosp Pharm
December 2024
Maxor National Pharmacy Services Corp, Amarillo, TX, USA.
This study examines the correlation between time-in-therapeutic range (TTR) and anticoagulation-related adverse events (AEs) in patients with atrial fibrillation (Afib) in a pharmacist-managed ambulatory care clinic. A single-center, retrospective cohort study was conducted at a community hospital-based outpatient anticoagulation clinic to investigate the predictive value of suboptimal TTR percentages for hemorrhagic or thromboembolic events in Afib patients. Eligible participants were aged 18 years or older, diagnosed with Afib, and receiving warfarin therapy as current or past enrollees in the anticoagulation management program.
View Article and Find Full Text PDFJAMA Cardiol
October 2024
Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain.
J Clin Med
June 2024
Surgical, Medical, Dental and Morphological Sciences Department (CHIMOMO), University of Modena and Reggio Emilia, 41126 Modena, Italy.
: The necessity of using central venous catheters (CVCs) in hemodialysis, coupled with their associated complications, remains a critical concern in nephrology. This study aims to compare the short-term prognosis of tunneled (T-CVC) and non-tunneled (NT-CVC) CVCs in acute hemodialysis patients, specifically focusing on infection rates, malpositioning, and lumen thrombosis within the first three weeks post-insertion. : A retrospective analysis was conducted on 176 CVCs placed between January and December 2023 at the Policlinico di Modena and the Ospedale Civile di Baggiovara.
View Article and Find Full Text PDFInt J Cardiol
June 2024
Herzzentrum Bonn, University Hospital Bonn, Germany; RheinAhrCardio, Praxis für Kardiologie, Bad-Neuenahr Ahrweiler, Germany. Electronic address:
Background: Advances in imaging have led to procedural optimization of left atrial appendage closure (LAAC). Contrast-free approaches, guided merely by echocardiography, have been established, however data on this topic remains scarce. In this analysis, we assessed contrast-free procedural results with the LAMBRE LAAC device.
View Article and Find Full Text PDFClin Neurol Neurosurg
February 2024
Department of Medicine, Grampians Health Ballarat, Australia; School of Medicine, Deakin University, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!